# Natera, Inc. – Consensus ‘buy’ rating and 11.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/natera-inc.consensus-buy-rating-and-11.7-upside-potential/4121152510
- Published: 2024-04-19T14:05:11+01:00
- Author: Charlotte Edwards

**Natera, Inc.** with ticker code (NTRA) now have 16 confirmed analysts covering
the stock with the consensus suggesting a rating of ‘buy’. The target price High/
Low ranges between $120.00 and $37.00 and has a mean target at $100.94. Given that
the stocks previous close was at $90.33 this would imply there is now a potential
upside of 11.7%. It’s also worth noting that there is a 50 day moving average of
$85.30 and the 200 moving average now moves to $61.03. The market cap for the company
is 10.54B. The stock price is currently at: $87.28 USD

 The potential market cap would be $11,777,739,757 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $9.41 and
a -19.67% return on assets.

Natera, Inc. is a diagnostics company that is focused on the development and commercialization
of molecular testing services, applying its technology in the fields of women’s 
health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology
combines its molecular assays, which reliably measure many informative regions across
the genome from samples as small as a single cell. The Company’s product offerings
include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening(
HCS), Spectrum Preimplantation Genetics, Anora Miscarriage Test (Anora) and Prospera.
The Company also offers Constellation, a cloud-based software platform that enables
laboratory customers to gain access through the cloud to the Company’s algorithms
and bioinformatics in order to validate and launch tests based on the Company’s 
technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as
in twin pregnancies, typically with a blood draw from the mother.

Share on:
